Table 1.
Study-level characteristics
| Author | Country of Origin | Year of Publication | Journal | Centers | Blinding | Study Type | Sampling Frame | Study Start Date | Study End Date | Trial ID | No. Patients Vinflunine | Median Age | Male | Female | No. Patients Stage IV | Median Follow-up (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aparicio et al31 | Spain | 2013 | European Journal of Cancer | multicenter | open label | case series | Retrospective | 10 | 10 | 10.5 | ||||||
| Bamias et al38 | Greece | 2016 | Clinical Genitourinary Cancer | multicenter | open label | case series | Retrospective | 1/1/2011 | 12/31/2013 | HGUCG | 36 | 68 | 31 | 5 | 36 | 16.8 |
| Bellmunt et al28 | Spain | 2010 | J Clin Oncol | multicenter | open label | RCT | Prospective | 5/15/2003 | 8/15/2006 | L00070 IN 302 | 253 | 64 | 292 | 78 | 370 | |
| Bellmunt et al7 | Spain | 2013 | Ann Oncol | multicenter | open label | RCT | Prospective | 5/15/2003 | 8/15/2006 | L00070 IN 302 | 253 | 64 | 42.9 | |||
| Bellmunt et al8 | Spain | 2009 | J Clin Oncol | multicenter | open label | RCT | Prospective | 5/15/2003 | 8/15/2006 | L00070 IN 302 | 253 | 64 | ||||
| Bellmunt et al22 | Spain | 2015 | Journal | multicenter | open label | RCT | Prospective | 4/15/2012 | 1/15/2015 | MAJA | 33 | 63 | 7.2 | |||
| Castellano et al35 | Spain | 2014 | BMC Cancer | multicenter | open label | case series | Retrospective | 12/15/2009 | 6/15/2013 | 102 | 67 | 102 | 8.9 | |||
| Chirivella et al39 | Spain | 2013 | European Journal of Cancer | multicenter | open label | case series | Retrospective | 4/15/2010 | 12/15/2012 | 45 | 68 | |||||
| Culine et al5 | UK | 2006 | Br J Cancer | multicenter | open label | phase II trial | Prospective | 11/15/2000 | 9/15/2002 | 51 | 63 | 41 | 17 | 58 | ||
| De Santis et al11 | Austria | 2016 | Ann Oncol | multicenter | open label | phase II trial | Prospective | 2/15/2011 | 8/15/2012 | JASINT1 | 69 | 70 | 69 | 25.9 | ||
| De Wit et al9 | Germany | 2015 | European Journal of Cancer | multicenter | open label | phase II trial | Prospective | 2/15/2012 | 7/15/2013 | JASiMA | 19 | 9 | ||||
| Di Lorenzo et al23 | Italy | 2015 | Medicine (Baltimore) | multicenter | open label | case series | Retrospective | 1/15/2010 | 1/15/2015 | 10 | 52 | |||||
| Di Palma et al29 | France | 2013 | European Journal of Cancer | multicenter | open label | case series | Retrospective | 11/15/2012 | 2/15/2013 | CURVE | 134 | |||||
| Donini et al40 | Italy | 2015 | Annals of Oncology | multicenter | open label | case series | Retrospective | 2/15/2011 | 6/15/2014 | MOVIE | 84 | 72 | 71 | 13 | 84 | |
| Facchini et al27 | Italy | 2016 | Front Pharmacol | single center | open label | case series | Retrospective | 2/15/2012 | 3/15/2015 | 43 | 63.5 | 40 | 3 | 43 | 24 | |
| Font et al10 | Spain | 2016 | Journal of Clinical Oncology | multicenter | open label | RCT | Prospective | 4/15/2012 | 1/15/2015 | MAJA | 45 | 64 | 88 | 12.2 | ||
| George et al41 | USA | 2007 | Ejc Supplements | multicenter | open label | phase II trial | Prospective | 114 | 66 | 88 | 26 | |||||
| Gerullis et al42 | Germany | 2013 | Anticancer Drugs | single center | open label | phase I trial | Prospective | 5/15/2011 | 12/15/2011 | NCT01265940 | 5 | 72 | 5 | 0 | 5 | |
| Guglieri-Lopez et al32 | Spain | 2015 | Anticancer Drugs | multicenter | open label | Cohort | Retrospective | 3/15/2010 | 11/15/2013 | 37 | 67 | 36 | 1 | 37 | ||
| Harshman et al30 | USA | 2013 | Br J Cancer | multicenter | open label | RCT | Prospective | 5/15/2003 | 8/15/2006 | L00070 IN 302 | 253 | 64 | 279 | 91 | 370 | 45.4 |
| Hegele et al43 | Germany | 2015 | Journal of Clinical Oncology | multicenter | open label | case series | Prospective | 77 | ||||||||
| Hegele et al44 | Germany | 2014 | Urol Int | multicenter | open label | case series | Retrospective | 2/15/2010 | 3/15/2012 | 21 | 63 | 19 | 2 | 21 | ||
| Holmsten et al45 | Sweden | 2016 | Oncol Lett | multicenter | open label | case series | Retrospective | 2/15/2010 | 7/15/2013 | 100 | 68 | 72 | 28 | 100 | ||
| Houede et al46 | France | 2016 | BMC Cancer | multicenter | open label | case series | Ambispective | 4/15/2013 | 4/15/2014 | 72 | 68 | 183 | 35 | |||
| Hussain et al47 | UK | 2015 | European Journal of Cancer | multicenter | open label | case series | Retrospective | 37 | 64 | 24 | 13 | 37 | ||||
| Marongiu et al24 | Italy | 2013 | European Urology, Supplements | multicenter | open label | case series | Retrosective | 1/1/2001 | 12/31/2013 | 40 | 67 | 40 | ||||
| Medioni et al36 | Italy | 2016 | BMC Cancer | multicenter | open label | case series | Retrosective | 1/1/2011 | 12/31/2011 | 134 | 65.3 | 119 | 15 | 134 | 17.6 | |
| Moriceau et al48 | France | 2015 | Clin Genitourin Cancer | single center | open label | case series | Retrospective | 5/15/2010 | 3/15/2014 | 19 | 66 | 18 | 1 | 19 | ||
| Palacka et al26 | Slovak Republic | 2014 | Klin Onkol | single center | open label | case series | Prospective | 4/15/2011 | 6/15/2014 | 16 | 62 | 13 | 3 | 16 | 5.2 | |
| Passalacqua et al49 | Italy | 2016 | Journal of Clinical Oncology | multicenter | open label | case series | Retrospective | 2/15/2011 | 6/15/2014 | MOVIE | 217 | 69 | 182 | 35 | 217 | |
| Pistamaltzian et al50 | Greece | 2016 | Anticancer Drugs | multicenter | open label | case series | Retrospective | 7/15/2005 | 7/15/2014 | 71 | 66.8 | 65 | 6 | 11.8 | ||
| Polo et al25 | Spain | 2014 | Journal of Clinical Oncology | multicenter | open label | RCT | Prospective | 4/15/2012 | 9/15/2013 | MAJA | 20 | 65.6 | 46 | |||
| Powles et al12 | UK | 2017 | EAS Meeting | multicenter | open label | RCT | Prospective | 1/13/2015 | 3/13/2017 | IMvigor211 | 250 | 67 | 195 | 55 | 233 | 17.3 |
| Retz et al51 | Germany | 2015 | BMC Cancer | multicenter | open label | case series | Prospective | 8/15/2010 | 9/15/2011 | NCT01103544 | 77 | 67 | 63 | 14 | 77 | 4.6 |
| Vaughn et al6 | USA | 2009 | Cancer | multicenter | open label | phase II trial | Prospective | 151 | 66 | 121 | 30 | 151 | 11.9 |
Abbreviations: RCT, randomized controlled trial; VIN, vinflunine.